Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fitzgerald Industries International
Acton, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
No active in-house clinical programs, but supplies key reagents (antibodies, proteins, ELISA kits) for diagnostics, research, and assay development in global biotech and pharma sectors. Acquired by Biosynth in May 2023, integrating its biologic and specialty reagent portfolio into a broader supply chain for the pharmaceutical and diagnostics industries[4][6].
- Modalities
- AntibodyProteinRecombinant ProteinELISA KitSerumPlasmaCytokineGrowth FactorSynthetic Reference Substance
- Industry
- Chemicals & Materials
Beyond the preview
Go deeper on Fitzgerald Industries International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fitzgerald Industries International.